CDRH has revised its draft guidance on the de novo classification process to align it with the FDA Safety and Innovation Act’s provisions that allow submission of de novo devices without a preceding 510(k) submission.
FDASIA, approved by Congress in July 2012, permitted streamlining of several of the agency’s device clearance and approval processes